Clinical Drug Investigation

, Volume 11, Issue 5, pp 300–304 | Cite as

Sumatriptan Delays Paracetamol Absorption in Migraine Patients

  • P. Usha Rani
  • M. U. R. Naidu
  • T. Ramesh Kumar Rao
  • S. Mohan Das
  • J. C. Shobha
  • K. Ravi Sekhar
  • E. Chandra Sekhar
  • T. Vijay Kumar
Clinical Pharmacokinetics

Summary

The effect of sumatriptan 100mg orally on paracetamol absorption was evaluated in 9 migraine patients. Sumatriptan pretreatment significantly lowered the peak paracetamol concentration and also delayed the time to reach peak concentration. The paracetamol peak concentration decreased significantly from 36.28 ± 10.85 mg/L to 18.26 ± 6.7 mg/L, and the time to reach the peak was significantly delayed from 1.36 ± 0.38 hours to 2.72 ± 1.0 hours after sumatriptan treatment. The rate of absorption of paracetamol up to 3 hours was significantly reduced after sumatriptan administration. At 2 hours after sumatriptan administration, only 67% of total paracetamol was absorbed, while the absorption was 97% without sumatriptan. The total absorption of paracetamol at the end of the 8th hour was, however, not affected. These results suggest that in migraine patients there is a delay in gastric emptying time with sumatriptan. Further studies are warranted during the acute attack to elucidate the clinical significance of the present study findings.

Keywords

Migraine Paracetamol Gastric Emptying Metoclopramide Sumatriptan 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Plosker GL, McTavish D. Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994; 47(4): 622–51PubMedCrossRefGoogle Scholar
  2. 2.
    Peroutka SJ. Drugs effective in the therapy of migraine. In: A Goodman Giman, TW Rail, AS Nies, et al., editors. Goodman and Gillman’s the pharmacological basis of therapeutics. 9th ed. New York: Pergamon Press, 1995; 489–501Google Scholar
  3. 3.
    Ramesh Kumar Rao T, Naidu MUR, Shobha JC, et al. Effect of a single oral dose of sumatriptan on paracetamol pharmacokinetics. Clin Drug Invest 1995; 10(4): 242–6CrossRefGoogle Scholar
  4. 4.
    Nimmo WS, Heading RC, Wilson J, et al. Inhibition of gastric emptying and drug absorption by narcotic analgesics. Br J Clin Pharmacol 1975; 1: 509–13CrossRefGoogle Scholar
  5. 5.
    Van Wyk M, Sommers De K, Meyer EC, et al. The mean cumulative fraction absorbed-time profiles of paracetamol as an index of gastric emptying. Methods Find Exp Clin Pharmacol 1990; 12: 291–4PubMedGoogle Scholar
  6. 6.
    Houghton LA, Fowler P, Keene ON, et al. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man. Aliment Pharmacol Ther 1992; 6(6): 685–91PubMedCrossRefGoogle Scholar
  7. 7.
    Nimmo WS. Drugs, disease and altered gatric emptying. Clin Pharmacokinet 1976; 1: 189–203PubMedCrossRefGoogle Scholar
  8. 8.
    Tokola RA. The effect of metoclopramide and prochlorperazine on the absoption of effervescent paracetamol in migraine. Cephalgia 1988; 8: 139–47CrossRefGoogle Scholar
  9. 9.
    Eadie MJ. Neurological diseases. In: Speight TM, editor. Avery’s Drug treatment. 3rd ed. Auckland: Adis Press, 1987: 1078–136Google Scholar
  10. 10.
    Volans GN. The effect of metoclopramide on the absorption of effervescent asprin in migraine. Br J Clin Pharmacol 1975; 2: 57PubMedGoogle Scholar
  11. 11.
    Ross-Lee LM, Eadie MJ, Heazlewood V, et al. Asprin pharmacokinetics in migraine. The effect of metoclopramide. Eur J Clin Pharmacol 1983; 24: 777–85PubMedCrossRefGoogle Scholar
  12. 12.
    Headache Classification Committee of the International Headache Society (1988). Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalgia 1988; 8 Suppl. 7: 1–93Google Scholar
  13. 13.
    Jung D, Zafar NU. Microhigh-performance liquid chromatographic assay of acetaminophen and its major metabolites in plasma and urine. J Chromatograph 1985; 339: 198–202CrossRefGoogle Scholar
  14. 14.
    Shargel L, Yu ABC. Pharmacokinetics of drug absorption. In: Applied biopharmaceutics and pharmacokinetics. 2nd ed. Connecticut: Appleton-Century-Crofts, 1985: 105–28Google Scholar
  15. 15.
    Glynn JP, Bastain W. Salivary excretion of paracetamol in man. J Pharm Pharmacol 1973; 25: 420–1PubMedCrossRefGoogle Scholar
  16. 16.
    Kamali F, Fry JR, Bell GD. Temporal variation in paracetamol absorption and metabolism in man. Xenobiotics 1987; 17: 635–42CrossRefGoogle Scholar
  17. 17.
    Miners JO, Attwood J, Birkett DJ. Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol 1983; 16: 503–9PubMedCrossRefGoogle Scholar
  18. 18.
    Mucklow JC, Fraser HS, Bulpitt CJ, et al. Environmental factors affecting paracetamol metabolism in London factory and office workers. Br J Clin Pharmacol 1980; 10: 67–74PubMedCrossRefGoogle Scholar
  19. 19.
    Welling PG. Interactions affecting drug absorption. Clin Pharmacokinet 1984; 9: 404PubMedCrossRefGoogle Scholar
  20. 20.
    Nimmo WS, Heading RC, Tothill P, et al. Pharmacological modification of gastric emptying: effects of propantheline and metoclopramide on paracetamol absorption. BMJ 1973; 1: 587PubMedCrossRefGoogle Scholar
  21. 21.
    Heading RC, Nimmo J, Prescott LF, et al. The dependence of paracetamol absorption on the rate of gastric emptying. Br J Pharmacol 1973; 47: 415–21PubMedCrossRefGoogle Scholar
  22. 22.
    Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291–4PubMedCrossRefGoogle Scholar
  23. 23.
    Dollery C. Sumatriptan. The therapeutic drugs. Vol. 2. Edinburgh: Churchill Livingstone 1991; S151–4Google Scholar
  24. 24.
    Pottage A, Campbell RWF, Achuff SC, et al. The absorption of oral mexiletine in coronary care patients. Eur J Clin Pharmacol 1978; 13: 393CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • P. Usha Rani
    • 1
  • M. U. R. Naidu
    • 1
  • T. Ramesh Kumar Rao
    • 1
  • S. Mohan Das
    • 1
  • J. C. Shobha
    • 1
  • K. Ravi Sekhar
    • 1
  • E. Chandra Sekhar
    • 1
  • T. Vijay Kumar
    • 1
  1. 1.Department of Clinical Pharmacology and TherapeuticsThe Nizam’s Institute of Medical SciencesPanjugutta, HyderabadIndia

Personalised recommendations